Articles On Regeneus (ASX:RGS)

Psychedelic drugs remain the talk of an otherwise depressed market today Newmont bid for Newcrest helps drive Materials sector higher ASX benchmark limps home to be down 0.25% at the end of a gloomy Monday   It’s not exactly been a stella...

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry   The US FDA announced last week that:...

The S&P ASX 200 rose 7.64%, in its best start to a year ever as global markets rally In a strong start to 2023 the S&P/ASX Emerging Companies index (XEC) rose ~8% in January Graphite explorer Lincoln Minerals soars more than 500% s...

Aussies warned of impending critical chicken meat shortage Data shows food prices rose a staggering 9.4% in Q4 CY2022 Lode Resources laughs all the way to the bank on the back of a 191.67% rise today   I don’t want to alarm anyone unduly,...

IMF says Everything’s War on Everything is great, except for the bad bits Short-sighted mortgage takers are bricking it over projected 4.1% interest rates in ‘23 Strong quarterlies have driven huge gains among well-placed small caps today...

Aussie markets expended a lot of energy to go precisely nowhere Guatam Adani left with less than US$93 billion after Hindenburg got into his shorts I had a really lovely holiday, and it’s great to be back at work. No, really…   It’s been...

Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past...

2023 off to a bit of a dismal start, down 1.3% on the opening day of trade GreenX soaring after rumblings from Poland over $1.3 billion payday Chinese markets gain before the rest of the trading world gets back from holidays   For about 1...

ASX health stocks have been out of favour this year with rotation away from growth to value sector Morgan’s Scott Power said a lot of biotechs aren’t able to convert their complex science into layman’s terms Hot money going to lithium and...

We take a look at how the 15 biotech IPOs that listed in 2021 are faring now Only two IPO stocks from 2021 have gained since listing We also look at the best and worst performing ASX stocks over the past month   There were 191 ASX IPOs in...

Blood clot programs have taken the spotlight recently as new discoveries made Two ASX health stocks are in the blood clot space Top performing ASX healthcare stocks in the past month Blood clots were top of biotech news this week after re...

US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F...

A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m...

Literally every sector had a red month, but mining was the worst PayGroup gets surprise $120m takeover offer from US unicorn Deel Tempest Minerals signed JV to explore near the Karara Magnetite Iron mine June was a month of global econom...

Highlights The healthcare sector comprises stocks from diversified backgrounds, including healthcare services, healthcare equipment, pharmaceuticals, biotechnology, etc. Last month, Living Cell Technologies (ASX:LCT) raised AU$1.285 mi...

Emerging Companies (XEC) index rises on Tuesday, up over 1.2% ASX 200 same, but a wee bit more Lode Resources rises sharply on more than just a sliver of silver   Everything’s higher on Tuesday. Not by a heap, but enough to cancel the co...

Regenerative medicine company Regeneus (ASX:RGS) has announced that its CEO Karolis Rosickas has purchased over 3.8 million shares in the company.

The Healthcare sector has been struggling as the pandemic wanes But most money managers are still bullish on the sector The biggest movements and news from ASX healthcare stocks this week  Dr Anthony Faucci, America’s top infectious disea...

The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite  A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot...

Biotech sector has had a tough time recently But there are signs of things improving this year A look at biotech movers on the ASX in the past fortnight Biotech stocks entered a bear phase in the middle of 2021, and things haven’t improve...

Telehealth was already a growing space even before the pandemic, but COVID had launched it into the mainstream. At the height of the pandemic in 2020, data from Research and Markets showed that 76% of hospitals in the US were using teleheal...

The ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial turn in the courts this week. The healthcare giant is currently staring down 38,000 claims that its talc products (including the famous baby...

At the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, beating the ASX200 benchmark index which was up 2.8% for the period. Here’s a table showing how ASX-listed healthcare stocks have been perform...

It’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. CODE COMPANY PRICE 1 WEEK RETURN %...

The life sciences sector has emerged into the spotlight ever since the pandemic began. In the US, the share prices of major vaccine-producing companies have surged astronomically as COVID-19  ravaged the world. Nasdaq-listed BioNTech, which...

It’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 losing it and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Name Price % Six Mont...

It’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 losing it and 16 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Company Price % Six M...

Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs on the ASX. Dimerix (ASX:DXB) jumped 45% during the month after announcing the commencement of ACTION 3, a Phase III study in pat...

ShareCafeFor a Life Free of Pain By Karolis Rosickas, Regeneus Chief Executive Officer   Regenerative medicine company Regeneus is at the forefront of providing a novel, stem cell-based therapy for knee osteoarthritis which afflicts hundred...

It’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 76 losing it and 23 flatlining. Rhinomed (ASX:RNO) was the biggest gainer, up a massive 85% for the fortnight after scoring a contract with N...

The ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the XHJ Health Sector and the ASX 200 benchmark rose by 3% over this period. A handful of ASX health stocks have seen their prices skyrocket du...

It’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 74 losing it and 21 flatlining. Analytica Limited (ASX:ALT) was the biggest gainer, up 25% from 8 to 20 July, followed by  Rhinomed (ASX:RNO)...

It’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52 losing it – and 21 flatlining. Botanix Pharma Ltd (ASX:BOT) was the biggest gainer, up 38% from 23 June to 7 July, and Suda Pharmaceuticals...

Here’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has returned 2.3 per cent for the last two weeks, compared to the broader market which rose by 2.7 per cent. The biggest news globally was out of U...

A recent article published in the Advance Science magazine discussed research by Monash University that uncovered a new technique to alter the shape of individual stem cells, which could potentially speed up recovery times for bone replacem...

Closing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers during the trading day. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intrad...

On Wednesday the S&P/ASX 200 Index (ASX: XJO) was in fine form and charged to new record high. The benchmark index rose 1% to 7,217.8 points. Will the market be able to build on this on Thursday? Here are five things to watch: ASX 200...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week Healthcare...

The Australian stock market marginally rose on Friday with S&P/ ASX200 gaining 0.27% to 7080.80 towards the end of the day, led by the travel stocks Webjet Limited (ASX:WEB) and Flight Centre Travel Group Limited (ASX:FLT) up 7.87% and...

Closing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intraday trade. WINNERS Scrol...

The benchmark index ASX 200 continues its upwards trajectory at the close, after the Reserve Bank of Australia (RBA) upgraded GDP growth forecast and committed to remain “highly accommodative” until 2024. The benchmark is up 21.5 points or...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

Here’s our fortnightly wrap of all the news driving ASX health stocks. It’s been a mixed two weeks for small-cap health companies, with 58 companies gaining ground and 54 losing it. Another 16 were flat. Code Company Price % return...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week With repor...

A quick wrap of the ASX’s key winners and losers on Tuesday, August 11. Data is taken after the market closes at 4pm EST. Stocks highlighted in yellow made market-moving announcements during the day. Today 675 stocks rose, 673 declined and...

Clinical-stage regenerative medicine company Regeneus (ASX: RGS) has signed a licence and collaboration agreement with Kyocera Corporation to develop and commercialise its lead stem cell platform technology Progenza for the treatment of kne...

Regeneus (ASX:RGS) has finally done that deal with Kyocera Corporation to develop and commercialise its stem cell treatment Progenza for knee osteoarthritis in Japan. The stock climbed as much as 81 per cent to an intra-day peak of 20c on T...

While treatments for pain management per se may not receive as much attention as those related to cures for chronic diseases, every day there is a large universe of people who attempt to treat but mismanage agonising and debilitating condit...